Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform
Recruiting now
Conditions studied: High-risk Cardiac Patients
In brief
The WILLEM Registry is a large-scale, single-group, observational, registry study to collect continuous clinical evidence of Willem in real-world settings. Cardiovascular diseases are a major problem for public health and healthcare systems. Electrocardiograms (ECGs) are simple tests which increase diagnostic performance and early detection of cardiovascular diseases. However, its interpretation is complex, time consuming for cardiology experts, and entails high costs for healthcare systems. Willem allows AI-based automatic interpretation and its performance has been examined in previous clinical trials, but additional clinical evidence is needed for its integration in real-world clinical settings. This study will collect clinical evidence of Willem performance to detect cardiac abnormalities in ECGs from high-risk cardiac patients admitted to cardiovascular units.
Key facts
- Study ID
- NCT07333547
- Run by
- Idoven 1903 S.L.
- People needed
- 200000
- Starts
- 2026-02-03
- Expected to finish
- 2036-01-01
- Last updated by the study team
- 2026-07-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- EC/IRB approval of ICF waiver prior to recruitment; otherwise, signed informed consent form by subject and investigator
- Age > 18 years-old, with no upper limit
- Subjects undergoing standard of care electrocardiogram (ECG) of any duration from any hardware device
- All available, but at least one, legible ECG tracings in raw data format (e.g. DICOM, XML, EDF, JSON, HL7, SCP, WFDB, CSV, etc.)
- Available subject clinical data associated with the ECG
- For 12-lead ECGs, a minimum length of 10 seconds at a minimum sample frequency of 250 Hz
- For ECGs from Holters, wearables, patches, insertable cardiac monitors, telemetries, etc., a minimum length of 30 seconds at a minimum sample frequency of 200 Hz with a lead I / II or its MCL-DII lead approximation
- For prospective eligibility only:
- Signed informed consent form, unless previously waived by the EC/IRB
- Site technical viability for ECG and subject clinical data transfer (e.g. end-to-end integration following interoperability standards such as FHIR, HL7 or DICOM)
You may not qualify if…
- Unavailable or suboptimal quality of the raw data from the ECG signal
- Age < 18 years-old
Where it is running
- Vanderbilt University Medical Center — Nashville, Tennessee, United States (enrolling)
- CardioHeredia — Guayaquil, Guayas, Ecuador (enrolling)
- Puerta de Hierro University Hospital — Madrid, Spain (enrolling)
- La Paz University Hospital — Madrid, Spain
- Murcia University — Murcia, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.